This chapter is the instrumentation layer. The compounds do the work. The labs tell you whether the work is happening at the level that matters — fat mass down, lean mass preserved, insulin sensitivity restored, inflammatory tone falling. Pull the wrong markers and you're flying blind on a 10-week protocol. Pull the right ones at the right cadence and the protocol tells you what it needs.
What's actually being measured — and why these five
The practitioner corpus converges on a small panel because most "comprehensive" labs measure lagging indicators. By the time LDL-C, HbA1c, and bone density move, the underlying biology has already shifted for years in either direction. The markers below are chosen because they move during a 10-week protocol — early enough to course-correct.
Fasting insulin and HOMA-IR. This is the most sensitive early-mover in the panel. HOMA-IR = (fasting insulin × fasting glucose) / 405. It quantifies how hard the pancreas is working to maintain euglycemia. The practitioner corpus is explicit: fasting insulin, the triglyceride-HDL ratio, and HOMA-IR are the highest-signal cheap markers in metabolic medicine. GLP-1 agonism drops fasting insulin fast — often within 4 weeks — because the compound is doing the work the pancreas used to do. Watch this number drop and you know the receptor-level mechanism is engaged. Watch it stay flat and you have a compliance, dose, or absorption problem.
HbA1c. This is a 90-day rolling average of glycation, so it is structurally a lagging indicator on a 10-week protocol. Real-world semaglutide cohort data shows HbA1c reductions of roughly 0.32% at the population level with average body weight loss of 3.86% — meaningful, but the curve doesn't fully express until month 6+. Pull HbA1c at baseline and Week 10. Do not pull it at Week 4 expecting movement; you will misread the noise.
Body composition via DEXA. The practitioner consensus is unambiguous: DEXA is the gold standard for body composition. It divides tissue into bone, fat, and "other" (mostly skeletal muscle) with sub-percent accuracy. Critically, DEXA separates visceral adipose tissue (VAT) from total fat — VAT is a small fraction of total fat mass but disproportionately predictive of metabolic risk. Scale weight cannot distinguish a 3-lb fat loss with 1-lb muscle gain (excellent recomp) from a 4-lb fat loss with zero muscle change (good) from a 2-lb fat loss with 2-lb muscle loss (failed protocol). DEXA can. Note the calibration quirk in the practitioner literature: DEXA reads systematically higher body fat % than calipers or BIA — adjust expectations up by ~3% if cross-referencing.
Appendicular lean mass index (ALMI). This is the marker the practitioner corpus flags as load-bearing for GLP-1 protocols specifically. ALMI = (lean mass in arms + legs) / height². GLP-1 agonists cause appetite suppression that, unmanaged, produces protein-deficient weight loss — and lean mass loss in the limbs is what predicts sarcopenia, frailty, and long-term metabolic decline. This is the single number that tells you whether your GLP-1 protocol is doing harm under the surface even while the scale falls.
hs-CRP. Inflammatory tone proxy. By the time someone feels inflammation, it's been burning for years. hs-CRP is the cheapest, most-validated systemic inflammation marker available. Adiposity drives inflammatory cytokine output (visceral fat is metabolically active and pro-inflammatory). As VAT falls on the protocol, hs-CRP should fall with it. Flat hs-CRP at Week 10 with apparent weight loss is a flag that either the loss is water/glycogen, the visceral compartment is unchanged, or there's an unrelated inflammatory driver (gut, oral, sleep) that the protocol won't fix.
The lab panel — baseline, Week 4, Week 10
| Marker | Baseline | Week 4 | Week 10 | Evidence Tier | What it tells you |
|---|---|---|---|---|---|
| Fasting insulin | ✅ | ✅ | ✅ | 🔵 Clinical | Receptor-level mechanism — drops first, drops fastest |
| Fasting glucose | ✅ | ✅ | ✅ | 🔵 Clinical | Pairs with insulin for HOMA-IR |
| HOMA-IR (calculated) | ✅ | ✅ | ✅ | 🔵 Clinical | Insulin resistance composite — the workhorse number |
| HbA1c | ✅ | — | ✅ | 🔵 Clinical | Lagging; only meaningful at Week 10 |
| Triglyceride : HDL ratio | ✅ | ✅ | ✅ | 🟢 Expert | Cheap proxy for insulin resistance and particle size |
| ApoB | ✅ | — | ✅ | 🔵 Clinical | Particle count — the causal lipid marker, not LDL-C |
| hs-CRP | ✅ | ✅ | ✅ | 🔵 Clinical | Systemic inflammatory tone — tracks VAT decline |
| DEXA scan | ✅ | — | ✅ | 🔵 Clinical | Fat mass, VAT, ALMI — the only true composition read |
| Liver enzymes (ALT/AST) | ✅ | — | ✅ | 🔵 Clinical | Hepatic fat shedding indicator |
| IGF-1 | ✅ | — | ✅ | 🟢 Expert | Baseline for any GH-secretagogue layer; not a weight marker |
DEXA cadence: baseline and Week 10 only. The practitioner corpus notes DEXA radiation is ~1/20 of a mammogram and ~½ of a cross-country flight — trivial, but the signal doesn't move fast enough to justify Week 4 imaging. Two scans bracket the protocol cleanly.
Leading vs lagging — which marker tells you what, and when
Leading indicators (move in Weeks 1–4):
- Fasting insulin — first to drop, often 20–40% reduction by Week 4 on a working GLP-1 protocol
- HOMA-IR — composite of the above, same timeline
- Trig:HDL ratio — triglycerides clear fast once hepatic insulin signaling improves
- hs-CRP — falls as visceral inflammation drops, often visible by Week 4
Lagging indicators (Week 10 and beyond):
- HbA1c — 90-day rolling average, structurally lagged
- ApoB — particle remodeling takes 8–12 weeks minimum
- DEXA fat mass — meaningful change requires the full 10-week intervention
- ALMI — moves slowly in either direction; this is the protection metric, not the progress metric
If Week 4 leading indicators are flat, the protocol isn't working — adjust dose, route, or compliance before continuing. If Week 4 leading indicators move but Week 10 lagging indicators don't, the receptor-level mechanism worked but the magnitude was insufficient for systemic remodeling.
What's NOT happening yet at Week 4
- HbA1c will not have moved meaningfully — do not pull it
- ApoB will not have remodeled — particle count is a Week 10+ read
- DEXA fat mass will not show clean separation from glycogen/water loss in the first 4 weeks
- Bone density will not have changed in either direction — this is a year-scale marker, not protocol-scale
- IGF-1 will not move from weight loss alone; it only matters if you're stacking a secretagogue
The decision framework
Three Week-4 scenarios drive the Phase 2 decision:
- Fasting insulin down ≥25%, hs-CRP falling, trig:HDL improving → protocol is engaging the mechanism. Continue current dose into Phase 2.
- Fasting insulin flat, weight down via appetite suppression alone → the compound is suppressing intake but not restoring receptor signaling. Either dose is sub-therapeutic, or there's an absorption issue. Adjust before Week 5.
- Fasting insulin down, but ALMI projecting low at Week 10 → protein intake is insufficient or training stimulus is absent. The protocol is working metabolically but harming you structurally. Layer protein and resistance training immediately — do not wait for Week 10 DEXA to confirm.
The corpus describes these markers and these cadences. Pull them, read them, adjust.